首页 > 最新文献

Infectious Medicine最新文献

英文 中文
Molecular evolution, virology and spatial distribution of HCV genotypes in Pakistan: A meta-analysis 巴基斯坦 HCV 基因型的分子进化、病毒学和空间分布:荟萃分析
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.007
Arslan Habib , Nadiya Habib , Khalid Mahmood Anjum , Riffat Iqbal , Zeeshan Ashraf , Muhammad Usman Taj , Muhammad Asim , Kanwal Javid , Faezeh Idoon , Saeid Dashti , Cassio Rocha Medeiros , Ana Pavla Almeida Diniz Gurgel , Henrique Douglas Melo Coutinho

Background

Hepatitis C, caused by the Hepatitis C Virus (HCV), is the second most common form of viral hepatitis. The geographical distribution of HCV genotypes can be quite complex, making it challenging to ascertain the most prevalent genotype in a specific area.

Methods

To address this, a review was conducted to determine the prevalence of HCV genotypes across various provinces and as a whole in Pakistan. The scientific literature regarding the prevalence, distribution, genotyping, and epidemiology of HCV was gathered from published articles spanning the years 1996–2020.

Results

Genotype 1 accounted for 5.1% of the patients, with its predominant subtype being 1a at 4.38%. The frequencies of its other subtypes, 1b and 1c, were observed to be 1.0% and 0.31% respectively. Genotype 2 had a frequency of 2.66%, with the most widely distributed subtype being 2a at 2.11% of the patients. Its other subtypes, 2b and 2c, had frequencies of 0.17% and 0.36% respectively. The most prevalent genotype among all isolates was 3 (65.35%), with the most frequent subtype being 3a (55.15%), followed by 3b (7.18%). The prevalence of genotypes 4, 5, and 6 were scarce in Pakistan, with frequencies of 0.97%, 0.08%, and 0.32% respectively. The prevalence of untypeable and mixed genotypes was 21.34% and 3.53% respectively. Estimating genotypes proves to be a productive method in assisting with the duration and selection of antiviral treatment. Different HCV genotypes can exhibit variations in their response to specific antiviral treatments. Different genotypes may have distinct natural histories, including variations in disease progression and severity. Some genotypes may lead to more rapid liver damage, while others progress more slowly.

Conclusions

This information can guide screening and testing strategies, helping to identify individuals at higher risk of developing severe complications. Studying the distribution of HCV genotypes in a population can provide valuable insights into the transmission dynamics of the virus.

背景丙型肝炎是由丙型肝炎病毒(HCV)引起的,是第二种最常见的病毒性肝炎。HCV 基因型的地理分布可能相当复杂,因此确定特定地区最流行的基因型具有挑战性。研究人员从 1996-2020 年间发表的文章中收集了有关 HCV 流行率、分布、基因分型和流行病学的科学文献。其他亚型 1b 和 1c 的频率分别为 1.0% 和 0.31%。基因型 2 的频率为 2.66%,其中分布最广的亚型为 2a,占患者总数的 2.11%。其他亚型 2b 和 2c 的频率分别为 0.17% 和 0.36%。在所有分离株中,最常见的基因型是 3(65.35%),最常见的亚型是 3a(55.15%),其次是 3b(7.18%)。基因型 4、5 和 6 在巴基斯坦很少见,频率分别为 0.97%、0.08% 和 0.32%。无法分型和混合基因型的发生率分别为 21.34% 和 3.53%。事实证明,估计基因型是一种有效的方法,有助于确定抗病毒治疗的疗程和选择。不同的 HCV 基因型对特定抗病毒治疗的反应可能不同。不同的基因型可能有不同的自然病史,包括疾病进展和严重程度的差异。结论这些信息可以指导筛查和检测策略,帮助识别出现严重并发症风险较高的人群。研究 HCV 基因型在人群中的分布可以为了解病毒的传播动态提供有价值的信息。
{"title":"Molecular evolution, virology and spatial distribution of HCV genotypes in Pakistan: A meta-analysis","authors":"Arslan Habib ,&nbsp;Nadiya Habib ,&nbsp;Khalid Mahmood Anjum ,&nbsp;Riffat Iqbal ,&nbsp;Zeeshan Ashraf ,&nbsp;Muhammad Usman Taj ,&nbsp;Muhammad Asim ,&nbsp;Kanwal Javid ,&nbsp;Faezeh Idoon ,&nbsp;Saeid Dashti ,&nbsp;Cassio Rocha Medeiros ,&nbsp;Ana Pavla Almeida Diniz Gurgel ,&nbsp;Henrique Douglas Melo Coutinho","doi":"10.1016/j.imj.2023.11.007","DOIUrl":"https://doi.org/10.1016/j.imj.2023.11.007","url":null,"abstract":"<div><h3>Background</h3><p>Hepatitis C, caused by the Hepatitis C Virus (HCV), is the second most common form of viral hepatitis. The geographical distribution of HCV genotypes can be quite complex, making it challenging to ascertain the most prevalent genotype in a specific area.</p></div><div><h3>Methods</h3><p>To address this, a review was conducted to determine the prevalence of HCV genotypes across various provinces and as a whole in Pakistan. The scientific literature regarding the prevalence, distribution, genotyping, and epidemiology of HCV was gathered from published articles spanning the years 1996–2020.</p></div><div><h3>Results</h3><p>Genotype 1 accounted for 5.1% of the patients, with its predominant subtype being 1a at 4.38%. The frequencies of its other subtypes, 1b and 1c, were observed to be 1.0% and 0.31% respectively. Genotype 2 had a frequency of 2.66%, with the most widely distributed subtype being 2a at 2.11% of the patients. Its other subtypes, 2b and 2c, had frequencies of 0.17% and 0.36% respectively. The most prevalent genotype among all isolates was 3 (65.35%), with the most frequent subtype being 3a (55.15%), followed by 3b (7.18%). The prevalence of genotypes 4, 5, and 6 were scarce in Pakistan, with frequencies of 0.97%, 0.08%, and 0.32% respectively. The prevalence of untypeable and mixed genotypes was 21.34% and 3.53% respectively. Estimating genotypes proves to be a productive method in assisting with the duration and selection of antiviral treatment. Different HCV genotypes can exhibit variations in their response to specific antiviral treatments. Different genotypes may have distinct natural histories, including variations in disease progression and severity. Some genotypes may lead to more rapid liver damage, while others progress more slowly.</p></div><div><h3>Conclusions</h3><p>This information can guide screening and testing strategies, helping to identify individuals at higher risk of developing severe complications. Studying the distribution of HCV genotypes in a population can provide valuable insights into the transmission dynamics of the virus.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 324-333"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X2300062X/pdfft?md5=57a8370dce8f385f0f8f4acbc58eb8e7&pid=1-s2.0-S2772431X2300062X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Persistent Nocardia beijingensis infection in a patient with postoperative abscess and misuse of antibiotics in China 中国一名术后脓肿患者的北京诺卡氏菌持续感染与抗生素的滥用
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.002
Lihua Qi , Weihong Fan , Jing Li , Hongfei Cui , Jianxia Xu , Dongmei Gu , Jiaojiao Meng , Jie Liu

Here we describe the first case of abscess infection caused by Nocardia beijingensis in China. The patient was immunocompetent but suffered from postoperative abscess for 6 years. This study highlights the necessity of long-term infected foci to be thoroughly examined to identify the pathogen, as well as the importance of accurate Nocardia identification and antimicrobial susceptibility tests for understanding the pathogen's epidemiology, clinical significance, and treatment strategy.

本文描述了中国首例由北京诺卡菌引起的脓肿感染病例。该患者免疫功能正常,但术后脓肿长达 6 年之久。这项研究强调了对长期感染病灶进行彻底检查以确定病原体的必要性,以及准确鉴定诺卡氏菌和进行抗菌药敏感性试验对于了解该病原体的流行病学、临床意义和治疗策略的重要性。
{"title":"Persistent Nocardia beijingensis infection in a patient with postoperative abscess and misuse of antibiotics in China","authors":"Lihua Qi ,&nbsp;Weihong Fan ,&nbsp;Jing Li ,&nbsp;Hongfei Cui ,&nbsp;Jianxia Xu ,&nbsp;Dongmei Gu ,&nbsp;Jiaojiao Meng ,&nbsp;Jie Liu","doi":"10.1016/j.imj.2023.11.002","DOIUrl":"10.1016/j.imj.2023.11.002","url":null,"abstract":"<div><p>Here we describe the first case of abscess infection caused by <em>Nocardia beijingensis</em> in China. The patient was immunocompetent but suffered from postoperative abscess for 6 years. This study highlights the necessity of long-term infected foci to be thoroughly examined to identify the pathogen, as well as the importance of accurate <em>Nocardia</em> identification and antimicrobial susceptibility tests for understanding the pathogen's epidemiology, clinical significance, and treatment strategy.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 343-348"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000576/pdfft?md5=ee13cccdedfd564cc3be09b140f6ecbd&pid=1-s2.0-S2772431X23000576-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135614319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SUPER Score Contributes to Warning and Management in Early-Stage COVID-19 SUPER 评分有助于早期 COVID-19 的预警和管理
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.09.003
Yuan Bian , Qi Han , Yue Zheng , Yu Yao , Xinhui Fan , Ruijuan Lv , Jiaojiao Pang , Feng Xu , Yuguo Chen

Background

Some COVID-19 patients deteriorate to severe cases with relatively higher case-fatality rates, which increases the medical burden. This necessitates identification of patients at risk of severe disease. Early assessment plays a crucial role in identifying patients at risk of severe disease. This study is to assess the effectiveness of SUPER score as a predictor of severe COVID-19 cases.

Methods

We consecutively enrolled COVID-19 patients admitted to a comprehensive medical center in Wuhan, China, and recorded clinical characteristics and laboratory indexes. The SUPER score was calculated using parameters including oxygen saturation, urine volume, pulse, emotional state, and respiratory rate. In addition, the area under the receiver operating characteristic curve (AUC), specificity, and sensitivity of the SUPER score for the diagnosis of severe COVID-19 were calculated and compared with the National Early Warning Score 2 (NEWS2).

Results

The SUPER score at admission, with a threshold of 4, exhibited good predictive performance for early identification of severe COVID-19 cases, yielding an AUC of 0.985 (95% confidence interval [CI] 0.897–1.000), sensitivity of 1.00 (95% CI 0.715–1.000), and specificity of 0.92 (95% CI 0.775–0.982), similar to NEWS2 (AUC 0.984; 95% CI 0.895–1.000, sensitivity 0.91; 95% CI 0.587–0.998, specificity 0.97; 95% CI 0.858–0.999). Compared with patients with a SUPER score<4, patients in the high-risk group exhibited lower lymphocyte counts, interleukin-2, interleukin-4 and higher fibrinogen, C-reactive protein, aspartate aminotransferase, and lactate dehydrogenase levels.

Conclusions

In conclusion, the SUPER score demonstrated equivalent accuracy to the NEWS2 score in predicting severe COVID-19. Its application in prognostic assessment therefore offers an effective early warning system for critical management and facilitating efficient allocation of health resources.

背景一些 COVID-19 患者病情恶化为重症病例,病死率相对较高,这增加了医疗负担。这就需要识别有重症风险的患者。早期评估在识别有严重疾病风险的患者方面起着至关重要的作用。本研究旨在评估 SUPER 评分作为 COVID-19 重症病例预测指标的有效性。使用血氧饱和度、尿量、脉搏、情绪状态和呼吸频率等参数计算 SUPER 评分。此外,还计算了 SUPER 评分诊断重症 COVID-19 的接收器操作特征曲线下面积(AUC)、特异性和灵敏度,并与国家早期预警评分 2(NEWS2)进行了比较。985(95% 置信区间 [CI] 0.897-1.000),灵敏度为 1.00(95% CI 0.715-1.000),特异度为 0.92(95% CI 0.775-0.982),与 NEWS2 相似(AUC 0.984; 95% CI 0.895-1.000,灵敏度 0.91; 95% CI 0.587-0.998,特异度 0.97; 95% CI 0.858-0.999)。与 SUPER 评分<4 的患者相比,高危组患者的淋巴细胞计数、白细胞介素-2 和白细胞介素-4 水平较低,纤维蛋白原、C 反应蛋白、天冬氨酸氨基转移酶和乳酸脱氢酶水平较高。因此,将其应用于预后评估可为危重症管理提供有效的早期预警系统,并促进医疗资源的有效分配。
{"title":"SUPER Score Contributes to Warning and Management in Early-Stage COVID-19","authors":"Yuan Bian ,&nbsp;Qi Han ,&nbsp;Yue Zheng ,&nbsp;Yu Yao ,&nbsp;Xinhui Fan ,&nbsp;Ruijuan Lv ,&nbsp;Jiaojiao Pang ,&nbsp;Feng Xu ,&nbsp;Yuguo Chen","doi":"10.1016/j.imj.2023.09.003","DOIUrl":"10.1016/j.imj.2023.09.003","url":null,"abstract":"<div><h3>Background</h3><p>Some COVID-19 patients deteriorate to severe cases with relatively higher case-fatality rates, which increases the medical burden. This necessitates identification of patients at risk of severe disease. Early assessment plays a crucial role in identifying patients at risk of severe disease. This study is to assess the effectiveness of SUPER score as a predictor of severe COVID-19 cases.</p></div><div><h3>Methods</h3><p>We consecutively enrolled COVID-19 patients admitted to a comprehensive medical center in Wuhan, China, and recorded clinical characteristics and laboratory indexes. The SUPER score was calculated using parameters including oxygen saturation, urine volume, pulse, emotional state, and respiratory rate. In addition, the area under the receiver operating characteristic curve (AUC), specificity, and sensitivity of the SUPER score for the diagnosis of severe COVID-19 were calculated and compared with the National Early Warning Score 2 (NEWS2).</p></div><div><h3>Results</h3><p>The SUPER score at admission, with a threshold of 4, exhibited good predictive performance for early identification of severe COVID-19 cases, yielding an AUC of 0.985 (95% confidence interval [CI] 0.897–1.000), sensitivity of 1.00 (95% CI 0.715–1.000), and specificity of 0.92 (95% CI 0.775–0.982), similar to NEWS2 (AUC 0.984; 95% CI 0.895–1.000, sensitivity 0.91; 95% CI 0.587–0.998, specificity 0.97; 95% CI 0.858–0.999). Compared with patients with a SUPER score&lt;4, patients in the high-risk group exhibited lower lymphocyte counts, interleukin-2, interleukin-4 and higher fibrinogen, C-reactive protein, aspartate aminotransferase, and lactate dehydrogenase levels.</p></div><div><h3>Conclusions</h3><p>In conclusion, the SUPER score demonstrated equivalent accuracy to the NEWS2 score in predicting severe COVID-19. Its application in prognostic assessment therefore offers an effective early warning system for critical management and facilitating efficient allocation of health resources.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 308-314"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000540/pdfft?md5=f8f981ef0eb3e49bfab32ba43008cd11&pid=1-s2.0-S2772431X23000540-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135922285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The presence of foci of Rickettsia conorii infection in China 中国存在康氏立克次体感染病灶
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.09.002
Nannan Xu , Hui Liu , Chunmei Qu , Sai Wen , Wenlu Zou , Caiyun Chang , Gang Wang

China is not considered as an endemic area of Rickettsia conorii, so there is no routine clinical way to diagnose this infection. This study aims to determine whether 2 febrile patients who had a tick bite in East China were indeed infected with R. conorii. The citrate synthase gene (gltA) was amplified with universal rickettsial primers by real-time fluorescent PCR from the patients’ blood samples. Nested PCR was used to amplify the outer membrane protein A gene (ompA) for positive specimens. PCR products were further identified and analyzed through nucleic acid sequencing. Positive amplification of the gltA and ompA genes was found in both patients. The nucleotide sequences (303 bp) of the ompA gene of the 2 patients had high homology (99%) with the R. conorii Indian tick typhus strain in GenBank. A more than 4-fold increase in IgG against R. conorii provided supportive evidence of SFG Rickettsia infection. And the rapid recovery after doxycycline treatment also supported a rickettsial cause for the disease. Physicians in East China should be aware of human infections with R. conorii. PCR-based diagnostic methods offer a rapid and precise way to diagnose rickettsiosis, improving patient identification and management.

中国并不是立克次体的流行区,因此没有常规的临床诊断方法。本研究旨在确定在华东地区被蜱虫叮咬的两名发热患者是否真的感染了康氏立克次体。研究人员使用通用立克次体引物,通过实时荧光定量PCR技术扩增了患者血样中的柠檬酸合成酶基因(gltA)。对阳性样本采用巢式 PCR 扩增外膜蛋白 A 基因(ombA)。通过核酸测序对 PCR 产物进行进一步鉴定和分析。两名患者的 gltA 和 ompA 基因均扩增阳性。两名患者的 ompA 基因核苷酸序列(303 bp)与 GenBank 中的 R. conorii 印度蜱斑疹伤寒菌株具有高度同源性(99%)。针对R. conorii的IgG增加了4倍多,为SFG立克次体感染提供了支持性证据。多西环素治疗后的迅速恢复也支持了立克次氏体感染的病因。华东地区的医生应警惕人类感染立克次体。基于PCR的诊断方法为立克次体病的诊断提供了一种快速、精确的途径,可提高患者的识别和管理水平。
{"title":"The presence of foci of Rickettsia conorii infection in China","authors":"Nannan Xu ,&nbsp;Hui Liu ,&nbsp;Chunmei Qu ,&nbsp;Sai Wen ,&nbsp;Wenlu Zou ,&nbsp;Caiyun Chang ,&nbsp;Gang Wang","doi":"10.1016/j.imj.2023.09.002","DOIUrl":"10.1016/j.imj.2023.09.002","url":null,"abstract":"<div><p>China is not considered as an endemic area of <em>Rickettsia conorii</em>, so there is no routine clinical way to diagnose this infection. This study aims to determine whether 2 febrile patients who had a tick bite in East China were indeed infected with <em>R. conorii.</em> The citrate synthase gene (<em>gltA</em>) was amplified with universal rickettsial primers by real-time fluorescent PCR from the patients’ blood samples. Nested PCR was used to amplify the outer membrane protein A gene (<em>ompA</em>) for positive specimens. PCR products were further identified and analyzed through nucleic acid sequencing. Positive amplification of the <em>gltA</em> and <em>ompA</em> genes was found in both patients. The nucleotide sequences (303 bp) of the <em>ompA</em> gene of the 2 patients had high homology (99%) with the <em>R. conorii</em> Indian tick typhus strain in GenBank. A more than 4-fold increase in IgG against <em>R. conorii</em> provided supportive evidence of SFG Rickettsia infection. And the rapid recovery after doxycycline treatment also supported a rickettsial cause for the disease. Physicians in East China should be aware of human infections with <em>R. conorii.</em> PCR-based diagnostic methods offer a rapid and precise way to diagnose rickettsiosis, improving patient identification and management.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 334-337"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X2300045X/pdfft?md5=9f6384bf1674c07115256aad5bee51f4&pid=1-s2.0-S2772431X2300045X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135348592","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety SARS-CoV-2 变种和疫苗综述:病毒特性、变异、疫苗功效和安全性
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.08.005
Md. Aminul Islam

The severe acute respiratory syndrome coronavirus disease 2 instigated by coronavirus disease of 2019 (COVID-19) has delivered an unfathomable obstruction that has touched all sectors worldwide. Despite new vaccine technologies and mass administration of booster doses, the virus persists, and unknown the ending of the pandemic for new variants and sub-variants. Moreover, whether leaning on home medications or using plant extracts is sufficient often to combat the virus has generated tremendous interest in the scientific fraternity. Different databases including PubMed, Scopus, Web of Science, and Google Scholar used to find published articles linked with related topics. Currently, COVID-19 third and fourth shots of vaccines are progressively administered worldwide, where some countries trail others by a significant margin. Many proteins related to viral activity have changed, possibly boosting the virus infectivity and making antibodies ineffective. This study will reminisce the viral genome, associated pathways for viral protein functions, variants, and their mutations. The current, comprehensive review will also provide information on vaccine technologies developed by several biotech companies and the efficacy of their doses, costs including boosters on a mass level. As no vaccine is working to protect fully against all the variants, the new proactive vaccine research needs to be conducted based on all variants, their sub-lineage, and mutations.

由 2019 年冠状病毒病(COVID-19)引发的严重急性呼吸系统综合征冠状病毒病 2 给全球各行各业带来了深不可测的阻碍。尽管采用了新的疫苗技术,并大规模注射了加强剂,但病毒依然存在,新变种和亚变种的大流行能否结束也不得而知。此外,依靠家庭用药或使用植物提取物是否足以对抗病毒也引起了科学界的极大兴趣。不同的数据库包括 PubMed、Scopus、Web of Science 和 Google Scholar,用于查找与相关主题相关的已发表文章。目前,COVID-19 第三针和第四针疫苗已在全球范围内逐步接种,但一些国家的接种率远远落后于其他国家。许多与病毒活性有关的蛋白质发生了变化,可能会增强病毒的感染力,使抗体失效。本研究将回顾病毒基因组、病毒蛋白功能的相关途径、变体及其突变。目前的全面审查还将提供有关几家生物技术公司开发的疫苗技术及其剂量的有效性、成本,包括大规模的增强剂的信息。由于没有一种疫苗能够完全预防所有变种,因此需要根据所有变种、其亚系和变异情况开展新的前瞻性疫苗研究。
{"title":"A review of SARS-CoV-2 variants and vaccines: Viral properties, mutations, vaccine efficacy, and safety","authors":"Md. Aminul Islam","doi":"10.1016/j.imj.2023.08.005","DOIUrl":"10.1016/j.imj.2023.08.005","url":null,"abstract":"<div><p>The severe acute respiratory syndrome coronavirus disease 2 instigated by coronavirus disease of 2019 (COVID-19) has delivered an unfathomable obstruction that has touched all sectors worldwide. Despite new vaccine technologies and mass administration of booster doses, the virus persists, and unknown the ending of the pandemic for new variants and sub-variants. Moreover, whether leaning on home medications or using plant extracts is sufficient often to combat the virus has generated tremendous interest in the scientific fraternity. Different databases including PubMed, Scopus, Web of Science, and Google Scholar used to find published articles linked with related topics. Currently, COVID-19 third and fourth shots of vaccines are progressively administered worldwide, where some countries trail others by a significant margin. Many proteins related to viral activity have changed, possibly boosting the virus infectivity and making antibodies ineffective. This study will reminisce the viral genome, associated pathways for viral protein functions, variants, and their mutations. The current, comprehensive review will also provide information on vaccine technologies developed by several biotech companies and the efficacy of their doses, costs including boosters on a mass level. As no vaccine is working to protect fully against all the variants, the new proactive vaccine research needs to be conducted based on all variants, their sub-lineage, and mutations.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 247-261"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000448/pdfft?md5=37b73576b07e4da7572a883b7b19b2d4&pid=1-s2.0-S2772431X23000448-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135890163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Monkeypox virus (MPXV): A Brief account of global spread, epidemiology, virology, clinical features, pathogenesis, and therapeutic interventions 猴痘病毒(MPXV):简述全球传播、流行病学、病毒学、临床特征、发病机制和治疗干预措施
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.001
Md Aminul Islam , Jubayer Mumin , Md Masudul Haque , Md. Azizul Haque , Ahrar Khan , Prosun Bhattacharya , Md Atiqul Haque

The largest monkeypox virus (MPXV) outbreak of the 21st century occurred in 2022, which caused epidemics in many countries. According to WHO, physical contact with infected persons, contaminated surfaces, or affected animals might be a source of this virus transmission. A febrile sickness including few symptoms found in MPX disease. Skin rash, lesions, fever, headache, fatigue, and muscle aches symptoms were observed commonly for this disease. Animal and in vitro, studies have shown that the antiviral medications cidofovir and brincidofovir are effective against MPXV. The first-generation vaccinia virus vaccine was developed in 1960, and it helped to protect against MPXV with its side effects. A second-generation vaccination with limitations was launched in 2000. However, the CDC advised vaccinations for risk groups in endemic countries, including positive patients and hospital employees. The JYNNEOS vaccine, administered in 2 doses, also provides protection from MPX. This article presents concisely the most recent findings regarding epidemiology, genomic transmission, signs and symptoms, pathogenesis, diagnosis, and therapeutic interventions for MPXV, which may be helpful to researchers and practitioners. WHO declared that MPX was no longer a global health emergency due to its declining case rate, and a number of countries have reported new incidences. Further research-based investigations must be carried out based on the 2022 outbreak.

2022 年爆发了 21 世纪最大的猴痘病毒(MPXV)疫情,在许多国家造成流行。据世卫组织称,与感染者、受污染表面或患病动物的身体接触可能是这种病毒的传播源。发热性疾病,包括 MPX 病的少数症状。皮疹、皮损、发烧、头痛、疲劳和肌肉酸痛是该病的常见症状。动物和体外研究表明,抗病毒药物西多福韦和布林昔多福韦对 MPXV 有效。第一代疫苗于 1960 年研制成功,有助于预防 MPXV,但有副作用。2000 年推出了第二代疫苗,但有一定的局限性。不过,疾病预防控制中心建议流行国家的高危人群接种疫苗,包括阳性患者和医院员工。分两次接种的 JYNNEOS 疫苗也可预防 MPX。本文简要介绍了有关 MPXV 流行病学、基因组传播、体征和症状、发病机制、诊断和治疗干预措施的最新研究成果,可能对研究人员和从业人员有所帮助。世卫组织宣布,由于 MPX 病例率下降,该疾病已不再是全球紧急卫生事件,但一些国家又报告了新的发病率。必须根据 2022 年的疫情开展进一步的研究调查。
{"title":"Monkeypox virus (MPXV): A Brief account of global spread, epidemiology, virology, clinical features, pathogenesis, and therapeutic interventions","authors":"Md Aminul Islam ,&nbsp;Jubayer Mumin ,&nbsp;Md Masudul Haque ,&nbsp;Md. Azizul Haque ,&nbsp;Ahrar Khan ,&nbsp;Prosun Bhattacharya ,&nbsp;Md Atiqul Haque","doi":"10.1016/j.imj.2023.11.001","DOIUrl":"10.1016/j.imj.2023.11.001","url":null,"abstract":"<div><p>The largest monkeypox virus (MPXV) outbreak of the 21st century occurred in 2022, which caused epidemics in many countries. According to WHO, physical contact with infected persons, contaminated surfaces, or affected animals might be a source of this virus transmission. A febrile sickness including few symptoms found in MPX disease. Skin rash, lesions, fever, headache, fatigue, and muscle aches symptoms were observed commonly for this disease. Animal and in vitro, studies have shown that the antiviral medications cidofovir and brincidofovir are effective against MPXV. The first-generation vaccinia virus vaccine was developed in 1960, and it helped to protect against MPXV with its side effects. A second-generation vaccination with limitations was launched in 2000. However, the CDC advised vaccinations for risk groups in endemic countries, including positive patients and hospital employees. The JYNNEOS vaccine, administered in 2 doses, also provides protection from MPX. This article presents concisely the most recent findings regarding epidemiology, genomic transmission, signs and symptoms, pathogenesis, diagnosis, and therapeutic interventions for MPXV, which may be helpful to researchers and practitioners. WHO declared that MPX was no longer a global health emergency due to its declining case rate, and a number of countries have reported new incidences. Further research-based investigations must be carried out based on the 2022 outbreak.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 262-272"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000564/pdfft?md5=dc2676d1c5c5c0f25465494fea43ec10&pid=1-s2.0-S2772431X23000564-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135455092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metal nanoparticles as inhibitors of enzymes and toxins of multidrug-resistant Staphylococcus aureus 作为耐多药金黄色葡萄球菌酶和毒素抑制剂的金属纳米粒子
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.006
Amruta A. Joshi, Ravindra H. Patil

Staphylococcus aureus is an aerobic Gram-positive spherical bacterium known to cause a broad range of infections worldwide. It is a major cause of infective skin and soft infections and severe and life-threatening conditions, such as pneumonia, bloodstream infections, and endocarditis. The emergence of drug-resistant strains of S aureus, particularly methicillin-resistant S aureus (MRSA), has become a significant concern in the healthcare community. Antibiotic-resistant S aureus is commonly acquired in hospitals and long-term care facilities. It often affects patients with weakened immune systems, those undergoing invasive medical procedures, or those who have been hospitalized for extended periods. In the US, S aureus is known to cause potentially fatal illnesses, such as toxic shock syndrome (TSS) and acute-onset toxic shock syndrome (TSS), which are characterized by fever and hypotension. It develops resistance to antibiotics through several mechanisms, such as the production of enzymes that inactivate antibiotics, target site modification, efflux pumps, and plasmid-mediated resistance. Therefore, preventing the spread of drug-resistant S aureus is needed, and there is an urgent need to explore novel approaches in the development of anti-staphylococcal agents. This article reviews the principal infections caused by S aureus, major virulence factors, mechanisms of resistance development, and nanotechnology-based solutions for the control of drug-resistant S aureus.

金黄色葡萄球菌(Staphylococcus aureus)是一种需氧革兰阳性球形细菌,在全球范围内可引起多种感染。它是造成皮肤和软组织感染以及肺炎、血流感染和心内膜炎等严重和危及生命的疾病的主要原因。金黄色葡萄球菌耐药菌株的出现,尤其是耐甲氧西林金黄色葡萄球菌(MRSA),已成为医疗保健界的一个重大问题。耐药金黄色葡萄球菌通常发生在医院和长期护理机构。它通常会影响免疫力低下的患者、接受侵入性医疗程序的患者或长期住院的患者。在美国,金黄色葡萄球菌可导致潜在的致命疾病,如中毒性休克综合症(TSS)和急性中毒性休克综合症(TSS),其特征是发热和低血压。它通过多种机制对抗生素产生耐药性,如产生使抗生素失活的酶、靶点修饰、外排泵和质粒介导的耐药性。因此,需要防止耐药金黄色葡萄球菌的传播,并迫切需要探索开发抗葡萄球菌药物的新方法。本文综述了金黄色葡萄球菌引起的主要感染、主要致病因素、耐药性产生机制以及基于纳米技术的耐药金黄色葡萄球菌控制解决方案。
{"title":"Metal nanoparticles as inhibitors of enzymes and toxins of multidrug-resistant Staphylococcus aureus","authors":"Amruta A. Joshi,&nbsp;Ravindra H. Patil","doi":"10.1016/j.imj.2023.11.006","DOIUrl":"https://doi.org/10.1016/j.imj.2023.11.006","url":null,"abstract":"<div><p><em>Staphylococcus aureus</em> is an aerobic Gram-positive spherical bacterium known to cause a broad range of infections worldwide. It is a major cause of infective skin and soft infections and severe and life-threatening conditions, such as pneumonia, bloodstream infections, and endocarditis. The emergence of drug-resistant strains of <em>S aureus</em>, particularly methicillin-resistant <em>S aureus</em> (MRSA), has become a significant concern in the healthcare community. Antibiotic-resistant <em>S aureus</em> is commonly acquired in hospitals and long-term care facilities. It often affects patients with weakened immune systems, those undergoing invasive medical procedures, or those who have been hospitalized for extended periods. In the US, <em>S aureus</em> is known to cause potentially fatal illnesses, such as toxic shock syndrome (TSS) and acute-onset toxic shock syndrome (TSS), which are characterized by fever and hypotension. It develops resistance to antibiotics through several mechanisms, such as the production of enzymes that inactivate antibiotics, target site modification, efflux pumps, and plasmid-mediated resistance. Therefore, preventing the spread of drug-resistant <em>S aureus</em> is needed, and there is an urgent need to explore novel approaches in the development of anti-<em>staphylococcal</em> agents. This article reviews the principal infections caused by <em>S aureus,</em> major virulence factors, mechanisms of resistance development, and nanotechnology-based solutions for the control of drug-resistant <em>S aureus</em>.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 294-307"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000618/pdfft?md5=05d120ded6f685c00dd65fb127a51b4b&pid=1-s2.0-S2772431X23000618-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739236","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chikungunya in Zhejiang Province, Southeast China 中国东南部浙江省的奇昆古尼亚病
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.005
Jiangping Ren , Feng Ling , Ying Liu , Jimin Sun

Background

Chikungunya is emerging and reemerging word-widely in the past decades. It is non-endemic in Zhejiang Province, Southeast China. Aedes albopictus, one of major vectors of chikungunya, is widely-distribution in Zhejiang, and autochthonous transmission is possible after introducing chikungunya virus.

Methods

Retrospectively collected the epidemiological, clinical and genetic data of chikungunya and conducted the descriptive analysis and gene sequence analysis.

Results

From 2008 to 2022, 29 chikungunya cases, including 26 overseas imported and 3 local cases, were reported and no cases died of chikungunya. More than half of the imported cases (53.85%) were from Southeast Asia. Seasonal peak of the imported cases was noted between August and September, and 42.31% cases onset in those 2 months. Eight prefecture-level cities and 16 counties reported cases during the study period, with Jinghua (27.59%) and Hangzhou (24.14%) reporting the largest number of cases. The 3 local cases were all reported in Qujiang, Quzhou in 2017. For imported cases, the male-female gender ratio was 2.71:1, 20–30 years old cases (46.15%) and commercial service (42.31%) accounted for the highest proportion. Clinically, fever (100%), fatigue (94.44%), arthralgia (79.17%), headache (71.43%) and erythra (65.22%) were the most common reported symptoms. Eight whole-genome sequences were obtained and belonged to East/Central/South African (ECSA) or Asian genotype.

Conclusions

With the change of immigration policy, the surveillance of chikungunya should be strengthened and the ability of the case discovery and diagnosis should be improved in Zhejiang in the post-COVID-19 era.

背景过去几十年来,基孔肯雅病在全球范围内不断出现和复发。在中国东南部的浙江省,基孔肯雅病尚未流行。方法回顾性收集基孔肯雅病的流行病学、临床和遗传学资料,进行描述性分析和基因序列分析。结果2008-2022年共报告29例基孔肯雅病例,其中26例为国外输入性病例,3例为本地病例,无死亡病例。超过一半的输入病例(53.85%)来自东南亚。8月至9月是输入性病例的季节性高峰,42.31%的病例在这两个月发病。研究期间有 8 个地级市和 16 个县报告了病例,其中以金华(27.59%)和杭州(24.14%)报告的病例数最多。3例本地病例均于2017年在衢州曲江报告。输入性病例中,男女性别比为2.71:1,20-30岁病例(46.15%)和商业服务性病例(42.31%)占比最高。临床症状以发热(100%)、乏力(94.44%)、关节痛(79.17%)、头痛(71.43%)和红斑(65.22%)最为常见。结论随着出入境政策的变化,后COVID-19时代浙江省应加强对基孔肯雅病的监测,提高病例发现和诊断能力。
{"title":"Chikungunya in Zhejiang Province, Southeast China","authors":"Jiangping Ren ,&nbsp;Feng Ling ,&nbsp;Ying Liu ,&nbsp;Jimin Sun","doi":"10.1016/j.imj.2023.11.005","DOIUrl":"https://doi.org/10.1016/j.imj.2023.11.005","url":null,"abstract":"<div><h3>Background</h3><p>Chikungunya is emerging and reemerging word-widely in the past decades. It is non-endemic in Zhejiang Province, Southeast China. Aedes albopictus, one of major vectors of chikungunya, is widely-distribution in Zhejiang, and autochthonous transmission is possible after introducing chikungunya virus.</p></div><div><h3>Methods</h3><p>Retrospectively collected the epidemiological, clinical and genetic data of chikungunya and conducted the descriptive analysis and gene sequence analysis.</p></div><div><h3>Results</h3><p>From 2008 to 2022, 29 chikungunya cases, including 26 overseas imported and 3 local cases, were reported and no cases died of chikungunya. More than half of the imported cases (53.85%) were from Southeast Asia. Seasonal peak of the imported cases was noted between August and September, and 42.31% cases onset in those 2 months. Eight prefecture-level cities and 16 counties reported cases during the study period, with Jinghua (27.59%) and Hangzhou (24.14%) reporting the largest number of cases. The 3 local cases were all reported in Qujiang, Quzhou in 2017. For imported cases, the male-female gender ratio was 2.71:1, 20–30 years old cases (46.15%) and commercial service (42.31%) accounted for the highest proportion. Clinically, fever (100%), fatigue (94.44%), arthralgia (79.17%), headache (71.43%) and erythra (65.22%) were the most common reported symptoms. Eight whole-genome sequences were obtained and belonged to East/Central/South African (ECSA) or Asian genotype.</p></div><div><h3>Conclusions</h3><p>With the change of immigration policy, the surveillance of chikungunya should be strengthened and the ability of the case discovery and diagnosis should be improved in Zhejiang in the post-COVID-19 era.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 315-323"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000606/pdfft?md5=292246ca3cd6d34e0030b537eec7a5e4&pid=1-s2.0-S2772431X23000606-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polymyxin sensitivity/resistance cosmopolitan status, epidemiology and prevalence among O1/O139 and non-O1/non-O139 Vibrio cholerae: A meta-analysis O1/O139和非O1/非O139霍乱弧菌对多粘菌素的敏感性/耐药性的世界性状况、流行病学和流行率:荟萃分析
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.004
Bright E. Igere , Hope Onohuean , Declan C. Iwu , Etinosa O. Igbinosa

Resistance/sensitivity to polymyxin-B (PB) antibiotic has been employed as one among other epidemiologically relevant biotyping-scheme for Vibrio cholerae into Classical/El Tor biotypes. However, recent studies have revealed some pitfalls bordering on PB-sensitivity/resistance (PBR/S) necessitating study. Current study assesses the PBR/S cosmopolitan prevalence, epidemiology/distribution among O1/O139 and nonO1/nonO139 V. cholerae strains. Relevant databases (Web of Science, Scopus and PubMed) were searched to retrieve data from environmental and clinical samples employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Random-effect-model (REM) and common-effect-model (CEM) of meta-analysis was performed to determine prevalence of PBR/S V. cholerae strains, describe the cosmopolitan epidemiological potentials and biotype relevance. Heterogeneity was determined by meta-regression and subgroup analyses. The pooled analyzed isolates from articles (7290), with sensitive and resistance are 2219 (30.44%) and 5028 (69.56%). Among these PB-sensitive strains, more than 1944 (26.67%) were O1 strains, 132 (1.81%) were nonO1 strains while mis-reported Classical biotype were 2080 (28.53) respectively indicating potential spread of variant/dual biotype. A significant PB-resistance was observed in the models (CEM = 0.66, 95% CI [0.65; 0.68], p-value = 0.001; REM = 0.83 [0.74; 0.90], p = 0.001) as both models had a high level of heterogeneity (I2 = 98.0%; df=332=1755.09,Qp=2.4932). Egger test (z = 5.4017, p < 0.0001) reveal publication bias by funnel plot asymmetry. The subgroup analysis for continents (Asia, Africa) and sources (acute diarrhea) revealed (98% CI (0.73; 0.93); 55% CI (0.20; 0.86)), and 92% CI (0.67; 0.98). The Epidemiological prevalence for El tor/variant/dual biotype showed 88% CI (0.78; 0.94) with O1 strains at 88% CI (0.78; 0.94). Such global prevalence, distribution/spread of phenotypes/genotypes necessitates updating the decades-long biotype classification scheme. An antibiotic stewardship in the post antibiotic era is suggestive/recommended. Also, there is need for holistic monitoring/evaluation of clinical/epidemiological relevance of the disseminating strains in endemic localities.

对多粘菌素-B(Polymyxin-B,PB)抗生素的耐药性/敏感性一直被用作霍乱弧菌经典/埃尔托生物型的流行病学相关生物分型方案之一。然而,最近的研究发现了一些与 PB 敏感性/耐药性(PBR/S)相关的隐患,因此有必要进行研究。本研究评估了 PBR/S 在 O1/O139 和非 O1/非 O139霍乱弧菌菌株中的世界性流行、流行病学/分布情况。采用系统综述和元分析首选报告项目(PRISMA)对相关数据库(Web of Science、Scopus 和 PubMed)进行检索,从环境和临床样本中获取数据。采用随机效应模型(REM)和共效模型(CEM)进行荟萃分析,以确定PBR/S霍乱弧菌菌株的流行率,描述世界性流行病学潜力和生物型相关性。通过元回归和亚组分析确定了异质性。汇总分析的文章分离株(7290 株)中,敏感株和耐药株分别为 2219 株(30.44%)和 5028 株(69.56%)。在这些对 PB 敏感的菌株中,超过 1944 株(26.67%)为 O1 菌株,132 株(1.81%)为非 O1 菌株,而误报的经典生物型分别为 2080 株(28.53%),这表明变异/双生物型有可能传播。由于两个模型都具有高度异质性(I2 = 98.0%;df=332=1755.09,Qp=2.4932),因此在模型中观察到了明显的 PB 抗性(CEM = 0.66,95% CI [0.65;0.68],p 值 = 0.001;REM = 0.83 [0.74;0.90],p = 0.001)。Egger 检验(z = 5.4017,p < 0.0001)通过漏斗图的不对称揭示了发表偏倚。对各大洲(亚洲、非洲)和病源(急性腹泻)进行的亚组分析显示(98% CI (0.73; 0.93);55% CI (0.20; 0.86))和 92% CI (0.67; 0.98)。El tor/变异/双生物型的流行率为 88% CI (0.78; 0.94),O1 菌株的流行率为 88% CI (0.78; 0.94)。由于表型/基因型在全球的流行、分布/扩散情况如此之广,因此有必要更新沿用了几十年的生物型分类方案。在后抗生素时代,抗生素管理是一种建议/推荐。此外,还需要对流行地区传播菌株的临床/流行病学相关性进行全面监测/评估。
{"title":"Polymyxin sensitivity/resistance cosmopolitan status, epidemiology and prevalence among O1/O139 and non-O1/non-O139 Vibrio cholerae: A meta-analysis","authors":"Bright E. Igere ,&nbsp;Hope Onohuean ,&nbsp;Declan C. Iwu ,&nbsp;Etinosa O. Igbinosa","doi":"10.1016/j.imj.2023.11.004","DOIUrl":"https://doi.org/10.1016/j.imj.2023.11.004","url":null,"abstract":"<div><p>Resistance/sensitivity to polymyxin-B (PB) antibiotic has been employed as one among other epidemiologically relevant biotyping-scheme for <em>Vibrio cholerae</em> into Classical/El Tor biotypes. However, recent studies have revealed some pitfalls bordering on PB-sensitivity/resistance (PBR/S) necessitating study. Current study assesses the PBR/S cosmopolitan prevalence, epidemiology/distribution among O1/O139 and nonO1/nonO139 <em>V. cholerae</em> strains. Relevant databases (Web of Science, Scopus and PubMed) were searched to retrieve data from environmental and clinical samples employing the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). Random-effect-model (REM) and common-effect-model (CEM) of meta-analysis was performed to determine prevalence of PBR/S <em>V. cholerae</em> strains, describe the cosmopolitan epidemiological potentials and biotype relevance. Heterogeneity was determined by meta-regression and subgroup analyses. The pooled analyzed isolates from articles (7290), with sensitive and resistance are 2219 (30.44%) and 5028 (69.56%). Among these PB-sensitive strains, more than 1944 (26.67%) were O1 strains, 132 (1.81%) were nonO1 strains while mis-reported Classical biotype were 2080 (28.53) respectively indicating potential spread of variant/dual biotype. A significant PB-resistance was observed in the models (CEM = 0.66, 95% CI [0.65; 0.68], <em>p</em>-value = 0.001; REM = 0.83 [0.74; 0.90], <em>p</em> = 0.001) as both models had a high level of heterogeneity (<em>I</em><sup>2</sup> = 98.0%; <span><math><mrow><msubsup><mrow></mrow><mrow><mi>d</mi><mi>f</mi><mo>=</mo><mn>33</mn></mrow><mn>2</mn></msubsup><mo>=</mo><mn>1755.09</mn></mrow></math></span><span><math><mrow><mo>,</mo><mspace></mspace><mi>Q</mi><mi>p</mi><mo>=</mo><mn>2.4932</mn></mrow></math></span>). Egger test (<em>z</em> = 5.4017, <em>p</em> &lt; 0.0001) reveal publication bias by funnel plot asymmetry. The subgroup analysis for continents (Asia, Africa) and sources (acute diarrhea) revealed (98% CI (0.73; 0.93); 55% CI (0.20; 0.86)), and 92% CI (0.67; 0.98). The Epidemiological prevalence for El tor/variant/dual biotype showed 88% CI (0.78; 0.94) with O1 strains at 88% CI (0.78; 0.94). Such global prevalence, distribution/spread of phenotypes/genotypes necessitates updating the decades-long biotype classification scheme. An antibiotic stewardship in the post antibiotic era is suggestive/recommended. Also, there is need for holistic monitoring/evaluation of clinical/epidemiological relevance of the disseminating strains in endemic localities.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 283-293"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X2300059X/pdfft?md5=23a67f0f06d27589af7112ba4f777a16&pid=1-s2.0-S2772431X2300059X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The awareness and acceptance of HPV vaccines among parents of primary and junior high school students in China: a meta-analysis 中国小学生和初中生家长对 HPV 疫苗的认知和接受程度:一项荟萃分析
Pub Date : 2023-12-01 DOI: 10.1016/j.imj.2023.11.003
Meimei Cui , Yun Wang , Zhen Liu , Congxiao Liu , Tianhua Niu , Dan Zhou , Ming Zhao , Min Zhang , Jingjing Jia , Limei Luo

The awareness and acceptance of the human papillomavirus (HPV) vaccines among Chinese primary and junior high school students is limited. A meta-analysis was conducted to evaluate the awareness of HPV and HPV vaccines, as well as the acceptance of HPV vaccines, providing evidence-based strategies to promote HPV vaccination. Based on the databases of CNKI, Wanfang, VIP, PubMed, Embase, and Cochrane library, the literatures about the awareness of HPV and HPV vaccines, as well as the acceptance of HPV vaccines among parents of primary and junior high school students were collected from the inception to June 2023. Subgroup analysis was used to find the source of heterogeneity. Publication bias was evaluated using funnel plots and Egger's test. Fifteen literatures with 21,853 participants were included. The pooled HPV awareness, HPV vaccine awareness and acceptance rates among parents of primary and junior high school students in China were 42.90% (95% CI: 33.34%–52.47%), 28.11% (95% CI: 18.20%–43.41%), and 55.29% (95% CI: 45.85%–64.36%), respectively. The survey period and the proportion of female parents were the heterogeneity in awareness of HPV and HPV vaccines, as well as acceptance of HPV vaccines by subgroup analysis. Additionally, regional distribution emerged as another significant source of heterogeneity in HPV vaccine acceptance. The primary cause for parents' reluctance to vaccinate their children was theirs worries about the safety of the vaccines (66.21%). Though the awareness of HPV and its vaccines was low among parents of primary and junior high school students in China, the acceptance of HPV vaccines was relatively high. Strengthening health education and publicity was crucial to enhance awareness and acceptance, promoting HPV vaccination for effective cervical cancer prevention.

中国小学生和初中生对人类乳头瘤病毒(HPV)疫苗的认识和接受程度有限。本研究进行了一项荟萃分析,以评估对人乳头瘤病毒和人乳头瘤病毒疫苗的认知度以及对人乳头瘤病毒疫苗的接受度,为促进人乳头瘤病毒疫苗接种提供循证策略。基于 CNKI、万方、VIP、PubMed、Embase 和 Cochrane 图书馆等数据库,收集了从开始到 2023 年 6 月有关小学生和初中生家长对 HPV 和 HPV 疫苗的认识以及对 HPV 疫苗的接受程度的文献。采用亚组分析找出异质性的来源。使用漏斗图和 Egger 检验评估了发表偏倚。共纳入 15 篇文献,21853 名参与者。中国小学生和初中生家长对HPV的知晓率、HPV疫苗的知晓率和接受率分别为42.90%(95% CI:33.34%-52.47%)、28.11%(95% CI:18.20%-43.41%)和55.29%(95% CI:45.85%-64.36%)。调查时期和女性家长的比例是对 HPV 和 HPV 疫苗认识的异质性,也是亚组分析中对 HPV 疫苗接受度的异质性。此外,地区分布也是 HPV 疫苗接受度异质性的另一个重要来源。家长不愿为子女接种疫苗的主要原因是担心疫苗的安全性(66.21%)。虽然我国小学生和初中生家长对 HPV 及其疫苗的知晓率较低,但对 HPV 疫苗的接受程度相对较高。加强健康教育和宣传对于提高疫苗的认知度和接受度,促进 HPV 疫苗接种,有效预防宫颈癌至关重要。
{"title":"The awareness and acceptance of HPV vaccines among parents of primary and junior high school students in China: a meta-analysis","authors":"Meimei Cui ,&nbsp;Yun Wang ,&nbsp;Zhen Liu ,&nbsp;Congxiao Liu ,&nbsp;Tianhua Niu ,&nbsp;Dan Zhou ,&nbsp;Ming Zhao ,&nbsp;Min Zhang ,&nbsp;Jingjing Jia ,&nbsp;Limei Luo","doi":"10.1016/j.imj.2023.11.003","DOIUrl":"https://doi.org/10.1016/j.imj.2023.11.003","url":null,"abstract":"<div><p>The awareness and acceptance of the human papillomavirus (HPV) vaccines among Chinese primary and junior high school students is limited. A meta-analysis was conducted to evaluate the awareness of HPV and HPV vaccines, as well as the acceptance of HPV vaccines, providing evidence-based strategies to promote HPV vaccination. Based on the databases of CNKI, Wanfang, VIP, PubMed, Embase, and Cochrane library, the literatures about the awareness of HPV and HPV vaccines, as well as the acceptance of HPV vaccines among parents of primary and junior high school students were collected from the inception to June 2023. Subgroup analysis was used to find the source of heterogeneity. Publication bias was evaluated using funnel plots and Egger's test. Fifteen literatures with 21,853 participants were included. The pooled HPV awareness, HPV vaccine awareness and acceptance rates among parents of primary and junior high school students in China were 42.90% (95% CI: 33.34%–52.47%), 28.11% (95% CI: 18.20%–43.41%), and 55.29% (95% CI: 45.85%–64.36%), respectively. The survey period and the proportion of female parents were the heterogeneity in awareness of HPV and HPV vaccines, as well as acceptance of HPV vaccines by subgroup analysis. Additionally, regional distribution emerged as another significant source of heterogeneity in HPV vaccine acceptance. The primary cause for parents' reluctance to vaccinate their children was theirs worries about the safety of the vaccines (66.21%). Though the awareness of HPV and its vaccines was low among parents of primary and junior high school students in China, the acceptance of HPV vaccines was relatively high. Strengthening health education and publicity was crucial to enhance awareness and acceptance, promoting HPV vaccination for effective cervical cancer prevention.</p></div>","PeriodicalId":100667,"journal":{"name":"Infectious Medicine","volume":"2 4","pages":"Pages 273-282"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772431X23000588/pdfft?md5=cccda5691275f128a4c366331989f0fa&pid=1-s2.0-S2772431X23000588-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138739234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Infectious Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1